NCT04291859View on ClinicalTrials.gov

Lu AF28996 in Participants With Parkinson's Disease (PD)

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

February 26, 2020

Primary Completion Date

October 29, 2025

Study Completion Date

February 4, 2026

Conditions
Parkinson Disease
Interventions
DRUG

Lu AF28996

capsule, orally, doses and dose escalation scheme will be decided upon at dosing conferences

Trial Locations (15)

14033

Caen Normandy University, Caen

20007

Georgetown University, Washington D.C.

30331

Atlanta Center for Medical Research, Atlanta

33009

Velocity, Hallandale

33980

Parkinson's Disease Treatment Center of SW FL, Port Charlotte

41013

Virgen Del Roccio, Seville

48334

QUEST Research Institute, Farmington Hills

68154

Neurology Consultants of Nebraska, Omaha

83527

Curiositas-ad-sanum, Hamburg

90720

CenExel Los Alamitos, Los Alamitos

96817

Hawaii Pacific Neuroscience, Honolulu

99202

Inland Nortwest Research, Spokane

8934 AD

QPS Netherlands BV, Leeuwarden

08035

Hospital Vall d´Hebron, Barcelona

08195

Hosp. General Catalunya, Mira-Sol

All Listed Sponsors
lead

H. Lundbeck A/S

INDUSTRY